Indivior Pharmaceuticals — Financial Results
SUBLOCADE Is Driving Nearly All of the Company's Growth
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| SUBLOCADE net revenue | $856M | $756M | +13% |
| SUBLOCADE share of total revenue | 69% | 64% | +5pp |
| U.S. SUBLOCADE net revenue | $794M | $704M | +13% |
SUBLOCADE is Indivior's injectable, once-monthly treatment for opioid use disorder, and it is clearly the engine of the business. The 13% revenue increase was split roughly evenly between actual volume growth (7%) and favorable adjustments to rebate estimates (6%). With the broader long-acting injectable market growing in the "high-teens" percentage range and SUBLOCADE holding roughly 75% of that market, the product's dominance looks well-established for now.
Total Revenue Rose Modestly, but Older Products Are Shrinking
| Product | 2025 | 2024 | Change |
|---|---|---|---|
| Sublingual & other (e.g., SUBOXONE Film) | $351M | $377M | -7% |
| PERSERIS | $24M | $40M | -39% |
| OPVEE | $8M | $15M | -49% |
| Total | $1,239M | $1,188M | +4% |
Overall revenue grew just 4%, because SUBLOCADE's gains were partially offset by declines across every other product line. SUBOXONE Film is losing market share to generics (its oral BMAT share fell from 16% to 14%), while PERSERIS and OPVEE are being wound down entirely. The company has flagged that total 2026 revenue is expected to decline compared to 2025.
Profit Surged, but Largely Due to a One-Time Drop in Legal Costs
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Operating income | $262M | $38M | +594% |
| Litigation settlement expenses | $13M | $195M | -$182M |
| Net income | $210M | $7M | NM |
The dramatic jump in operating income is mostly explained by a $182 million swing in litigation settlement expenses (legal costs paid to resolve lawsuits), not an improvement in the core business economics. Strip that out and the underlying profit improvement is far more modest. Gross margin (the percentage of revenue left after production costs) was essentially flat at 80%.
A Major Restructuring Is Underway, With $127 Million in One-Time Costs
In mid-2025, Indivior launched the Indivior Action Agenda, a multi-year plan to simplify the business. This included cutting staff, consolidating offices, and announcing an exit from several international markets including the U.K., Ireland, Sweden, Israel, Finland, and Italy. The restructuring cost $127 million in 2025 across redundancy payments, asset write-downs, and consulting fees. Management expects these actions to substantially reduce operating expenses in 2026.
Cash Position Fell and Operating Cash Flow Turned Negative
| Metric | 2025 | 2024 |
|---|---|---|
| Cash & investments | $222M | $347M |
| Operating cash flow | -$27M | +$36M |
Cash dropped by $125 million, and operating cash flow (cash generated by running the business day-to-day) turned negative at -$27 million. The main reason was $208 million more in litigation settlement payments in 2025, including an early payoff of amounts owed to the U.S. Department of Justice. This is largely a timing issue rather than a sign the business is losing money operationally, but it leaves the company with a noticeably thinner cash cushion heading into 2026.